We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

50 hedge funds and large institutions have $81.3M invested in Catalyst Pharmaceutical in 2014 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more call options, than puts

Call options by funds: $142K | Put options by funds: $49K

60% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 10

3% more capital invested

Capital invested by funds: $78.7M → $81.3M (+$2.61M)

4% less funds holding

Funds holding: 52 → 50 (-2)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

Holders
50
Holders Change
-2
Holders Change %
-3.85%
% of All Funds
1.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
16
Reduced
10
Closed
12
Calls
$142K
Puts
$49K
Net Calls
+$93K
Net Calls Change
-$790K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$9.6M
2
BC
Broadfin Capital
New York
+$2.74M
3
PCA
Private Capital Advisors
Connecticut
+$2.27M
4
SFM
Sphera Funds Management
Israel
+$1.03M
5
GTC
Ghost Tree Capital
New York
+$686K

Top Sellers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
-$4.43M
2
VAM
Visium Asset Management
New York
-$2.08M
3
Morgan Stanley
Morgan Stanley
New York
-$1.58M
4
Renaissance Technologies
Renaissance Technologies
New York
-$652K
5
Millennium Management
Millennium Management
New York
-$275K

CPRX Hedge Fund Activity: Q4 2014 in Review

50 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2014, worth a combined $81.3M — up 3.3% from $78.7M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CPRX and 10 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 16 added.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $9.6M. The largest seller was Federated Hermes, cutting an estimated $4.43M.

  • 50 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2014, down from 52 in Q3 2014.
  • Funds reported $81.3M of Catalyst Pharmaceutical stock for Q4 2014, up 3.3% quarter-over-quarter.
  • 10 funds opened new Catalyst Pharmaceutical positions in Q4 2014 and 12 closed out, a net change of -2 holders.
  • The largest Catalyst Pharmaceutical buyer in Q4 2014 was Point72 Asset Management, an estimated $9.6M added.
  • The largest Catalyst Pharmaceutical seller in Q4 2014 was Federated Hermes, an estimated $4.43M sold.

Based on aggregated 13F filings for Q4 2014.